Law Office of Brodsky & Smith, LLC Announces Investigation of Cardiac Science Corporation

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors Cardiac Science Corporation (“Cardiac Science”) or the “Company”) (Nasdaq:CSCX) relating to the proposed acquisition by Opto Circuits Limited (“Opto”).

Under the terms of the transaction, Cardiac Science shareholders would receive cash of $2.30 for each share of Cardiac Science stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law. The transaction appears to be unfair, in part, given that the offer represents no premium over the $2.47 a share Cardiac Science stock traded at as recently as August 4, 2010 and an analyst set a price target for Cardiac Science at $6.00 per share. Thus, shareholders need additional information to know if the Board of Directors breached their fiduciary duties by failing to adequately shop the Company, which has resulted in Opto underpaying for the company.

If you own shares of Cardiac Science and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at investorrelations@brodsky-smith.com, visiting http://brodsky-smith.com/240-cscx-cardiac-science-corporation.html, or by calling toll free 877-LEGAL-90.